Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

New Formulation Approval: Roche’s Tecentriq® SC (atezolizumab) Approved by EC

Jan 16, 2024

Roche announced that the European Commission (EC) has granted it marketing authorisation for Tecentriq® SC (atezolizumab) for subcutaneous injection.  The new authorisation applies to all indications already approved for the previous formulation of Tecentriq® (administered by IV infusion) including various lung, liver, bladder and breast cancers.

The Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Tecentriq® SC (the new formulation) on 14 November 2023.